Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,628
archived clinical trials in
Schizophrenia

Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
St. Christopher's Hospital for Children
mi
from
Philadelphia, PA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
St. Christopher's Hospital for Children
mi
from
Philadelphia, PA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Center For Emotional Fitness
mi
from
Cherry Hill, NJ
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Center For Emotional Fitness
mi
from
Cherry Hill, NJ
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
CRI Worldwide, LLC
mi
from
Philadelphia, PA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
CRI Worldwide, LLC
mi
from
Philadelphia, PA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Albuquerque Neuroscience Inc.
mi
from
Albuquerque, NM
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Albuquerque Neuroscience Inc.
mi
from
Albuquerque, NM
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Neurobehavioral Research, Inc.
mi
from
Cedarhurst, NY
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Neurobehavioral Research, Inc.
mi
from
Cedarhurst, NY
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Comprehensive Neuroscience
mi
from
Fresh Meadows, NY
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Comprehensive Neuroscience
mi
from
Fresh Meadows, NY
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Division of Psychiatry Research - Zucker Hills Hospital
mi
from
Glen Oaks, NY
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Division of Psychiatry Research - Zucker Hills Hospital
mi
from
Glen Oaks, NY
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Finger Lakes Clinical Research
mi
from
Rochester, NY
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Finger Lakes Clinical Research
mi
from
Rochester, NY
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Richmond Behavioral Associates
mi
from
Staten Island, NY
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Richmond Behavioral Associates
mi
from
Staten Island, NY
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Behavioral Medical Research of Staten Island
mi
from
Staten Island, NY
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Behavioral Medical Research of Staten Island
mi
from
Staten Island, NY
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
North Coast Clinical Trials, Inc.
mi
from
Beachwood, OH
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
North Coast Clinical Trials, Inc.
mi
from
Beachwood, OH
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Neuro-Pain Medical Center
mi
from
Fresno, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Neuro-Pain Medical Center
mi
from
Fresno, CA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
SP Research, PLLC
mi
from
Oklahoma City, OK
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
SP Research, PLLC
mi
from
Oklahoma City, OK
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
IPS Research
mi
from
Oklahoma City, OK
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
IPS Research
mi
from
Oklahoma City, OK
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
CRI Worldwide
mi
from
Mt Laurel, NJ
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
CRI Worldwide
mi
from
Mt Laurel, NJ
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Belmont Center for Comprehensive Treatment
mi
from
Philadelphia, PA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Belmont Center for Comprehensive Treatment
mi
from
Philadelphia, PA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Carolina Clinical Trials, Inc
mi
from
Charleston, SC
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Carolina Clinical Trials, Inc
mi
from
Charleston, SC
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Community Clinical Research
mi
from
Austin, TX
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Community Clinical Research
mi
from
Austin, TX
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
KRK Medical Research
mi
from
Dallas, TX
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
KRK Medical Research
mi
from
Dallas, TX
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
FutureSearch Clinical Trials, LP
mi
from
Dallas, TX
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
FutureSearch Clinical Trials, LP
mi
from
Dallas, TX
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
InSite Clinical Research
mi
from
Southwest, TX
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
InSite Clinical Research
mi
from
Southwest, TX
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Claghorn-Lesem Research Clinic
mi
from
Houston, TX
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Claghorn-Lesem Research Clinic
mi
from
Houston, TX
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Bayou City Research Limited
mi
from
Houston, TX
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Bayou City Research Limited
mi
from
Houston, TX
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Mary Ann Knesevich, MD, PA
mi
from
Irving, TX
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Mary Ann Knesevich, MD, PA
mi
from
Irving, TX
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Frontier Institute
mi
from
Spokane, WA
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Status: Archived
Updated: 1/1/1970
Frontier Institute
mi
from
Spokane, WA
Smoking Abstinence and Lapse Effects in Smokers With Schizophrenia and Controls
Smoking Abstinence and Lapse Effects in Smokers With Schizophrenia and Controls
Status: Archived
Brown Univerity
mi
from
Providence, RI
Smoking Abstinence and Lapse Effects in Smokers With Schizophrenia and Controls
Smoking Abstinence and Lapse Effects in Smokers With Schizophrenia and Controls
Status: Archived
Updated: 1/1/1970
Brown Univerity
mi
from
Providence, RI
Effects of Antipsychotics on Eating and Food Craving in People With Schizophrenia
Effects of Antipsychotics on Eating and Food Craving in People With Schizophrenia
Status: Archived
University of Maryland, Baltimore
mi
from
Baltimore, MD
Effects of Antipsychotics on Eating and Food Craving in People With Schizophrenia
Effects of Antipsychotics on Eating and Food Craving in People With Schizophrenia
Status: Archived
Updated: 1/1/1970
University of Maryland, Baltimore
mi
from
Baltimore, MD
Nicotinic Receptor Density in Smoking and Nonsmoking Schizophrenics
PET Assay of Acetylcholine Beta2* Nicotinic Receptor Density in Smoking and Non-Smoking Schizophrenics
Status: Archived
Johns Hopkins University
mi
from
Baltimore, MD
Nicotinic Receptor Density in Smoking and Nonsmoking Schizophrenics
PET Assay of Acetylcholine Beta2* Nicotinic Receptor Density in Smoking and Non-Smoking Schizophrenics
Status: Archived
Updated: 1/1/1970
Johns Hopkins University
mi
from
Baltimore, MD
Nicotinic Receptor Density in Smoking and Nonsmoking Schizophrenics
PET Assay of Acetylcholine Beta2* Nicotinic Receptor Density in Smoking and Non-Smoking Schizophrenics
Status: Archived
Maryland Psychiatric Research Center
mi
from
Baltimore, MD
Nicotinic Receptor Density in Smoking and Nonsmoking Schizophrenics
PET Assay of Acetylcholine Beta2* Nicotinic Receptor Density in Smoking and Non-Smoking Schizophrenics
Status: Archived
Updated: 1/1/1970
Maryland Psychiatric Research Center
mi
from
Baltimore, MD
Studies of Frontal Lobe Brain Functioning in Schizophrenia
Studies of Frontal Lobe Function During Cognitive Stimulation as Measured With Oxygen-15 Water Positron Emission Tomography in Normal Subjects and Patients With Neuropsychiatric Disorders
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Studies of Frontal Lobe Brain Functioning in Schizophrenia
Studies of Frontal Lobe Function During Cognitive Stimulation as Measured With Oxygen-15 Water Positron Emission Tomography in Normal Subjects and Patients With Neuropsychiatric Disorders
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Brain Tissue Collection for Neuropathological Studies
Brain Procurement for the Human Brain Collection Core
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Brain Tissue Collection for Neuropathological Studies
Brain Procurement for the Human Brain Collection Core
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Brain Tissue Collection for Neuropathological Studies
Brain Procurement for the Human Brain Collection Core
Status: Enrolling
Updated:  12/31/1969
Office of the Chief Medical Examiner
mi
from
Fairfax, VA
Brain Tissue Collection for Neuropathological Studies
Brain Procurement for the Human Brain Collection Core
Status: Enrolling
Updated: 12/31/1969
Office of the Chief Medical Examiner
mi
from
Fairfax, VA
Click here to add this to my saved trials
Brain Tissue Collection for Neuropathological Studies
Brain Procurement for the Human Brain Collection Core
Status: Enrolling
Updated:  12/31/1969
Office of the Chief Medical Examiner
mi
from
Washington,
Brain Tissue Collection for Neuropathological Studies
Brain Procurement for the Human Brain Collection Core
Status: Enrolling
Updated: 12/31/1969
Office of the Chief Medical Examiner
mi
from
Washington,
Click here to add this to my saved trials
Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers
Structural and Functional Imaging of Neuropsychiatric Patients and Normal Volunteers With 1.5 Tesla MRI
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers
Structural and Functional Imaging of Neuropsychiatric Patients and Normal Volunteers With 1.5 Tesla MRI
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Electrophysiology and Blood Flow in Patients With Schizophrenia and Their Siblings
Integrating EEG/MEG and fMRI: Activity Correlation Between Frontal and Temporal Lobe Structures in Schizophrenic Patients, Their Siblings and Unrelated Normal Volunteers
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Electrophysiology and Blood Flow in Patients With Schizophrenia and Their Siblings
Integrating EEG/MEG and fMRI: Activity Correlation Between Frontal and Temporal Lobe Structures in Schizophrenic Patients, Their Siblings and Unrelated Normal Volunteers
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Clinical Trial of Tolcapone for Cognition in Schizophrenia
Randomized, Double-Blinded, Placebo Controlled Study of the Effects of Tolcapone and Entacapone on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Clinical Trial of Tolcapone for Cognition in Schizophrenia
Randomized, Double-Blinded, Placebo Controlled Study of the Effects of Tolcapone and Entacapone on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia
Atypical Antipsychotics and P50 Sensory Gating
Status: Enrolling
Updated:  12/31/1969
Denver VAMC
mi
from
Denver, CO
Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia
Atypical Antipsychotics and P50 Sensory Gating
Status: Enrolling
Updated: 12/31/1969
Denver VAMC
mi
from
Denver, CO
Click here to add this to my saved trials
Treating Schizophrenia by Correcting Abnormal Brain Development
Addition of Tiagabine to Second-Generation Antipsychotics in the Treatment of Recent-Onset Schizophrenia by Modification of Developmental Reorganization of the Prefrontal Cortex
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Treating Schizophrenia by Correcting Abnormal Brain Development
Addition of Tiagabine to Second-Generation Antipsychotics in the Treatment of Recent-Onset Schizophrenia by Modification of Developmental Reorganization of the Prefrontal Cortex
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Treatment of Mania Symptoms With Drug Therapy
Divalproex Extended Release and Placebo, Lithium, or Quetiapine for Mania
Status: Enrolling
Updated:  12/31/1969
VA Palo Alto Health Care System
mi
from
Palo Alto, CA
Treatment of Mania Symptoms With Drug Therapy
Divalproex Extended Release and Placebo, Lithium, or Quetiapine for Mania
Status: Enrolling
Updated: 12/31/1969
VA Palo Alto Health Care System
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Side Effects of Newer Antipsychotics in Older Adults
Metabolic Effects of Newer Antipsychotics in Older Patients
Status: Enrolling
Updated:  12/31/1969
University of California, San Diego
mi
from
San Diego, CA
Side Effects of Newer Antipsychotics in Older Adults
Metabolic Effects of Newer Antipsychotics in Older Patients
Status: Enrolling
Updated: 12/31/1969
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Optimizing Response in Psychosis Study
Optimizing Response in Psychosis Study
Status: Enrolling
Updated:  12/31/1969
The Zucker Hillside Hospital
mi
from
Glen Oaks, NY
Optimizing Response in Psychosis Study
Optimizing Response in Psychosis Study
Status: Enrolling
Updated: 12/31/1969
The Zucker Hillside Hospital
mi
from
Glen Oaks, NY
Click here to add this to my saved trials
Optimizing Response in Psychosis Study
Optimizing Response in Psychosis Study
Status: Enrolling
Updated:  12/31/1969
SUNY Downstate Medical Center
mi
from
Brooklyn, NY
Optimizing Response in Psychosis Study
Optimizing Response in Psychosis Study
Status: Enrolling
Updated: 12/31/1969
SUNY Downstate Medical Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Direct Measurements of Cardiometabolic Risk in Treated Schizophrenia Patients
Direct Measurements of Cardiometabolic Risk in Treated Schizophrenia Patients
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Direct Measurements of Cardiometabolic Risk in Treated Schizophrenia Patients
Direct Measurements of Cardiometabolic Risk in Treated Schizophrenia Patients
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Varenicline Effects In Schizophrenic Smokers
Evaluation of Varenicline's Clinical Efficacy for Continued Smoking Abstinence When Used in the Clinical Treatment of Schizophrenic Patients Hospitalized in an Institution With a Ban on Cigarette Smoking
Status: Enrolling
Updated:  12/31/1969
Manhattan Psychiatric Center
mi
from
New York, NY
Varenicline Effects In Schizophrenic Smokers
Evaluation of Varenicline's Clinical Efficacy for Continued Smoking Abstinence When Used in the Clinical Treatment of Schizophrenic Patients Hospitalized in an Institution With a Ban on Cigarette Smoking
Status: Enrolling
Updated: 12/31/1969
Manhattan Psychiatric Center
mi
from
New York, NY
Click here to add this to my saved trials
Sensorimotor Gating in Schizophrenia
Sensorimotor Gating in Schizophrenia
Status: Enrolling
Updated:  12/31/1969
Atlanta VA Medical Center
mi
from
Decatur, GA
Sensorimotor Gating in Schizophrenia
Sensorimotor Gating in Schizophrenia
Status: Enrolling
Updated: 12/31/1969
Atlanta VA Medical Center
mi
from
Decatur, GA
Click here to add this to my saved trials
First Episode Schizophrenia and Cannabis-Related Disorder Study
Clozapine Vs. Risperidone for People With First Episode Schizophrenia and Co-Occurring Substance Use Disorder
Status: Enrolling
Updated:  12/31/1969
New Hampshire Hospital
mi
from
Concord, NH
First Episode Schizophrenia and Cannabis-Related Disorder Study
Clozapine Vs. Risperidone for People With First Episode Schizophrenia and Co-Occurring Substance Use Disorder
Status: Enrolling
Updated: 12/31/1969
New Hampshire Hospital
mi
from
Concord, NH
Click here to add this to my saved trials
First Episode Schizophrenia and Cannabis-Related Disorder Study
Clozapine Vs. Risperidone for People With First Episode Schizophrenia and Co-Occurring Substance Use Disorder
Status: Enrolling
Updated:  12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
First Episode Schizophrenia and Cannabis-Related Disorder Study
Clozapine Vs. Risperidone for People With First Episode Schizophrenia and Co-Occurring Substance Use Disorder
Status: Enrolling
Updated: 12/31/1969
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
First Episode Schizophrenia and Cannabis-Related Disorder Study
Clozapine Vs. Risperidone for People With First Episode Schizophrenia and Co-Occurring Substance Use Disorder
Status: Enrolling
Updated:  12/31/1969
West Central Behavioral Health
mi
from
Lebanon, NH
First Episode Schizophrenia and Cannabis-Related Disorder Study
Clozapine Vs. Risperidone for People With First Episode Schizophrenia and Co-Occurring Substance Use Disorder
Status: Enrolling
Updated: 12/31/1969
West Central Behavioral Health
mi
from
Lebanon, NH
Click here to add this to my saved trials
First Episode Schizophrenia and Cannabis-Related Disorder Study
Clozapine Vs. Risperidone for People With First Episode Schizophrenia and Co-Occurring Substance Use Disorder
Status: Enrolling
Updated:  12/31/1969
Mental Health Center of Greater Manchester
mi
from
Manchester, NH
First Episode Schizophrenia and Cannabis-Related Disorder Study
Clozapine Vs. Risperidone for People With First Episode Schizophrenia and Co-Occurring Substance Use Disorder
Status: Enrolling
Updated: 12/31/1969
Mental Health Center of Greater Manchester
mi
from
Manchester, NH
Click here to add this to my saved trials
First Episode Schizophrenia and Cannabis-Related Disorder Study
Clozapine Vs. Risperidone for People With First Episode Schizophrenia and Co-Occurring Substance Use Disorder
Status: Enrolling
Updated:  12/31/1969
Center for Psychiatric Advancement & Community Council of Nashua
mi
from
Nashua, NH
First Episode Schizophrenia and Cannabis-Related Disorder Study
Clozapine Vs. Risperidone for People With First Episode Schizophrenia and Co-Occurring Substance Use Disorder
Status: Enrolling
Updated: 12/31/1969
Center for Psychiatric Advancement & Community Council of Nashua
mi
from
Nashua, NH
Click here to add this to my saved trials